FORMULATION, DEVELOPMENT AND IN VITRO EVALUATION BEZAFIBRATE FAST DISSOLVING TABLETSg[p[pv

This study aimed to formulate, develop, and evaluate fast-dissolving tablets of bezafibrate using the solid dispersion method. The formulation process focused on enhancing the dissolution rate and bioavailability of bezafibrate, a poorly water-soluble drug. Precompression parameters such as thickness, diameter, hardness, friability, drug content, and weight variation were optimized to ensure the quality and uniformity of the tablets. In vitro evaluation involved assessing dispersion time, wetting time, and dissolution profiles over a three-month period to determine stability under different storage conditions. The findings suggest that the developed bezafibrate fast-dissolving tablets hold promise for improved drug delivery and patient compliance, offering valuable insights into their formulation and performance.

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-04-16
DOI
https://doi.org/10.5281/zenodo.19627463
Primary Topic
Drug Solubulity and Delivery Systems
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

FORMULATION, DEVELOPMENT AND IN VITRO EVALUATION BEZAFIBRATE FAST DISSOLVING TABLETSg[p[pv

Dr. P. Perumal, S. Selvaraj*, K. Manimekala
Zenodo (CERN European Organization for Nuclear Research)
Drug Solubulity and Delivery Systems
article

FORMULATION, DEVELOPMENT AND IN VITRO EVALUATION BEZAFIBRATE FAST DISSOLVING TABLETSg[p[pv

Dr. P. Perumal, S. Selvaraj*, K. Manimekala
article en

Abstract

This study aimed to formulate, develop, and evaluate fast-dissolving tablets of bezafibrate using the solid dispersion method. The formulation process focused on enhancing the dissolution rate and bioavailability of bezafibrate, a poorly water-soluble drug. Precompression parameters such as thickness, diameter, hardness, friability, drug content, and weight variation were optimized to ensure the quality and uniformity of the tablets. In vitro evaluation involved assessing dispersion time, wetting time, and dissolution profiles over a three-month period to determine stability under different storage conditions. The findings suggest that the developed bezafibrate fast-dissolving tablets hold promise for improved drug delivery and patient compliance, offering valuable insights into their formulation and performance.

Zenodo (CERN European Organization for Nuclear Research)
Openalex Percentile: Top 6%
Drug Solubulity and Delivery Systems
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.